Team

Sareen Lab

Led by Dr. Dhruv Sareen at the Cedars-Sinai Biomanufacturing Center — a 25,000 sq ft cGMP facility built for clinical-grade cell and gene therapy manufacturing.

DS

Photo coming soon

Title

Chief Biomanufacturing Officer & Executive Director

Institution

Cedars-Sinai Medical Center

Associate Professor

Also

Director, iPSC Core

Board of Governors Regenerative Medicine Institute

62+Publications
32+Patents
1,200+iPSC Lines
8+GMP iPSC Lines
25+Years in science

Principal Investigator

Dhruv Sareen, PhD

Building next-generation cell and gene therapy platforms — accelerating clinical translation with iPSC technology at the core, at scale and at speed.

Dhruv Sareen is the founding Executive Director and Chief Biomanufacturing Officer of the Cedars-Sinai Biomanufacturing Center — a 25,000 sq ft cGMP facility with ISO-certified cleanroom suites, automated differentiation labs, and AI-integrated bioprocessing infrastructure built to support human IND-enabling clinical trials.

His lab develops iPSC-derived cell therapy platforms across vascular, metabolic, cardiac, and neurological disease, with a unified manufacturing backbone spanning allogeneic and autologous programs. He led the Answer ALS consortium's iPSC biorepository — the world's largest, with over 1,200 patient lines and more than 4,000 clonal iPSCs distributed globally. The CBC operates as a Partnership Development Manufacturing Organization (PDMO): an academic-industrial engine providing cGMP manufacturing services, incubating early-stage companies, and translating novel therapies toward IND.

Education

Postdoctoral Fellow, Stem Cells & Neuroscience

University of Wisconsin–Madison · 2007–2010

PhD, Biomolecular Chemistry

University of Wisconsin–Madison · 2002–2007

BTech, Chemical Technology

University of Mumbai Institute of Chemical Technology · 1998–2002

Affiliations

NIIMBL CommitteeCIRM CGT Mfg. NetworkISSCR Standards Task ForceISCTARMEyestem Research (Founder)LA Mission College Biotech Advisory Board

Grant Portfolio

Selected grant funding.

Active — PI / Co-PI

01PI
2026–2028

Breakthrough T1D

Scalable GMP manufacturing of iPSC-derived insulin-producing cells

$600K

02Co-PI
2025–2026

Breakthrough T1D / UHN

Process development with clinical-grade iPSC lines for beta cell biomanufacturing facility

$871K

03PI
2020–2024

DoD / MTEC

Quality management processes for hiPSC-derived vascular cell therapies

$3.12M

04PI
2020–2024

NASA / Space Tango

Stem cell production capabilities for ISS

$500K

Active — Co-Investigator

05Co-I
2023–2028

CIRM INFR5

CGT Manufacturing Network — comprehensive biomanufacturing center

$7.96M total

06Co-I
2025–2028

NIH NIDDK

Personalized cystic fibrosis therapy — iPSC CF organ models

$1.24M/yr

07Co-I
2022–2026

NIH NHLBI

Mechanisms of sex-biased risk in aneurysm — Marfan iPSC models

$1.67M

08Co-I
2022–2027

NIH NICHD

Placental organoids to model preeclampsia

$2.09M

09Co-I
2023–2027

NIH NCI

Nanoimmunodrug for glioma — GMP translation

$2.73M

10Co-I
2026–2030

NIH NIDDK

Advanced in vitro model systems — digestive disease research core

$1.43M

Selected Past Funding

11PI
2023–2025

CIRM Infrastructure

Biomanufacturing center solving CGT bottlenecks

$2M

12Co-I
2016–2024

Answer ALS

ALS iPSC and motor neuron biorepository

$2.85M

13Co-I
2014–2020

NIH LINCS

NeuroLINCS multi-omics — neuron and glial signatures

$196K (CSMC)

14Co-PI
2016–2019

CIRM Translational

Personalized cell therapy for diabetes

The Team

Lab members.

Full profiles coming soon. Reach out at Dhruv.Sareen@cshs.org for lab inquiries.

SC

Staff Scientist

iPSC Core Operations

RA

Research Associate

Cell Therapy Manufacturing

PD

Postdoctoral Fellow

Vascular Biology

PD

Postdoctoral Fellow

Islet Differentiation

GS

Graduate Student

Bioengineered Tissues

GS

Graduate Student

Neurological Disease

BS

Bioinformatics Scientist

Multi-omics & AI

PM

Program Manager

GMP Operations